ASCO 2024

Prognostic value of ctDNA in therapeutic strategies;…

Immunotherapy makes a difference in survival in eTNBC

Personalized neoadjuvant therapy for high-risk breast…

Adjuvant endocrine therapy for ER-low EBC

AI for the prediction of disease progression

ctDNA important for HR+ eBC?

ctDNA analysis in monarchE

Advantage for node-negative patients

One step closer to chemo-free therapy for HR+/HER2+…

Expanding T-DxD use to HER2 ultra-low - the success…

Reassuring and clarifying new data for CDK4/6…

Is there still a place for endocrine therapy in HER2+…

ER-low: endocrine therapy necessary after all?

Eribulin, Trastuzumab, Pertuzumab in 1stL HER2+ mBC

Heterogenity of ER+ disease

Systemic therapy of HER2+ patients with brain…

New data on the omission of chemotherapy in young…

Triple positive mBC - chemotherapy unnecessary?

Leptomeningeal metastases in HER2+ mBC

The ADC revolution continues - ctDNA takes the next…

Broaden T-DXD as therapy standard for HER2low and…

Ultra low - ultra good?

Novel ADC-ICI combination therapy

Expanding use of T-DxD in HER2low and HER2 ultra-low…

Sacituzumab tirumotecan - a new powerful ADC for…

Important OS benefit with T-Dxd in HER2+ mBC

Decreasing SG related toxicity with profilatic G-CFS

HER2+ mBC 1stL T-Dxd

INAVO120 - updated results

Endocrine therapy with Palbociclib + Trastuzumab

CDK4/6 rechallenge

CDK4/6i effective in premenopausal patients as well

First-line inavolisib/placebo + palbociclib +…

Chemo-free regimen in HER2+ luminal breast cancer

Already more in the 1stL?

Chemo-free, CDK4/6 inhibitor-based combination active…

Disminución de la toxicidad relacionada con la OS con…

Regime senza chemioterapia nel carcinoma mammario…

Sacituzumab tirumotecan – nowy aktywny koniugat w…

INAVO120: risultati aggiornati

CDK4/6 rechallenge

Leczenie bez chemioterapii, oparte na inhibitorze…

C'è ancora posto per la terapia endocrina nel BC HER2+?

La révolution de l'ADC se poursuit / ctDNA franchit une…

Espansione dell'uso di T-DxD nelle pazienti con…

Importante beneficio en la supervivencia global con…

Focus on Quality of Life

Interesting data - but not practice changing

Is the metformin story over? How to treat HFNS…

Unlocking Insights: The ALLIANCE Trial redefining…

ARASENS Post hoc analysis: Therapy after progression

The evolving role of PSMA-PET with new agents

mCRPC: Who benefits from which measures?

EMBARK: Quality of Life

EMBARK demonstrates the importance of HRQoL benefit in…

RCT in mCRPC

Deciphering EMBARK: Exploring Enzalutamide's Impact on…

mCRCP CYCLONE 2 study

Unveiling the Potential: PSMA-PET in Prostate Cancer…

Important QoL data

Radionukleotides - the next step forward

Perioperative treamtent in MIBC - new data for the use…

Effect of an immune diet on the outcome after radical…

Biomarkers and long-term outcomes in pts with low tumor…

Quality of life not affected by i. v. Pembro

What to do with Cis Gem Nivo?

MI-UC - News from EVP standard

Modified FOLFIRINOX therapy as a good option for…

Preoperative use of sacituzumab govitecan

ctDNA as a biomarker in metastatic bladder cancer

ASCO 2024: Time for the rare GU tumors?

The Role of Topoisomerase Inhibitors in the…

Interim analysis of the SURE-01/02 study

ASCO24: Bladder cancer highlights

Biomarcadores y resultados a largo plazo en pacientes…

ASCO 2024: momento para los tumores GU poco frequentes?

El futuro de sacituzumab govitecan

ASCO24: Bladder cancer highlights

Evaluating risk criteria and monotherapy in mRCC

Advancing our understanding of biological mechanisms…

Advancing Our Understanding of Biological Mechanisms…

Combination is superior to monotherapy - how do we…

KIM-1: Will have a major impact

Biomarker analysis of KN426 & CLEAR

New HIF inhibitor in clear cell RCC

The never ending saga of biomarkers

Metastasized chromophobe RCC

nccRCC

New IMDC risk group - very favorable

Combination therapies for chromophobe renal cell…

NIVO+CABO: significantly longer therapy-free time

Treatment of favorable prognosis mRCC patients:…

Another breakthrough perioperative

KIM-1 - old wine in new bottles

The search of the ideal biomarker in advanced renal…

Belzutifan in earlier lines in advanced ccRCC

DFF332 a novel HIF inhibitor

La busqueda del marcador ideal en el cancer renal…

Adjuvant therapy: how to identify patients who will…

ctDNA predicts outcome in patients treated with…

Confirmed efficacy of periop IO in N2 R-NSCLC

Perioperative chemotherapy and N2 status

Osimertinib improves PFS in stage III

4y follow-up of CheckMate 816

Early change in SOC in EGFR+ LD-NSCLC

Stadium III EGFR+: now permanently Osimertinib?!

4-year efficacy of Keynote-799 and ctDNA

Liquid biopsy in curative situation

CheckMate 816: 4-year update

Le traitement adjuvant par osimertinib apres CTRT : …

Cambio temprano en el tratamiento estándar del EGFR+…

KRAS in NSCLC - a lot to come

TROP2-targeting ADCs: where a we heading?

Lorlatinib with extraordinary data in ALK + NSCLC

KRAS building on single agent therapy

KRASG12C - the story continues

ALK+ NSCLC - CROWN revisited

ADCs - moving landscapes. Subgroups remain to be…

EGFR+ NSCLC - amivantamab-based combination therapy

Lorlatinib convincing in ALK mutation 1st line

Confirmed efficacy in PD-L1 negativity - CheckMate 9LA

Adagrasib for KRASG12C mutation 2nd line

Telehealth is just as effective as a face-to-face visit…

ASCO 2024 highlights

Subcut amivantamab - the future

BAY2927088 - Promising Her2-Inhibitor in NSCLC

The end for local therapy for oligometastatic disease

Het einde van lokale therapie voor oligometastatische…

BAY297088 - Inhibiteur Her2-Inhibitor dans le NSCLC

La télésanté est aussi efficace qu'une consultation…

ASCO 2024 highlights

KRASG12C - het verhaal gaat verder

New SoC for LD-SCLC

Tarlatamab shows activity in patients with brain…

Maintenance with durvalumab is the new SOC after…

Finally, change for LS-SCLC

Le traitement d'entretien avec le durvalumab est le…

Harsh to beat

Is adjuvant treatment still standard in macroscopic,…

Is the triplet ready for phase 3?

10 years follow up - immunotherapy for BRAF-mutated…

Personalized mRNA-vaccination: Practice changer of the…

Is the induction treatment the new strategy for…

A new therapy benchmark for brain-met melanoma patients

3-year update on mRNA vaccines in melanoma

Longterm survival after adjuvant targeted therapy

Intralesional therapy with Daromun

Neoadjuvant intratumoral therapy with Daromun in…

Survival data for TT with dabrafenib and trametinib

Vaccine in combination with nivolumab for PDL1…

mRNA vaccine plus pembrolizumab in adjuvant therapy

Adjuvant therapy with dabrafenib and trametinib - final…

Consolidation of the use of IO in clinically detectable…

Progress in neoadjuvant therapy with IO

TIL therapy for metastatic melanoma

A new triplet for metastatic melanoma

New oncolytic immunotherapy (RP1) after PD-1 failure

Lentigo maligna therapy

Triple checkpoint blockade - a new approach?

Impactful studies from ASCO 24 III: Cell-therapy

Emerging rescue therapies for PD1 refractory melanoma

Neoadjuvant immunotherapy treatment for melanoma

Impactful studies from ASCO 24 I: NADINA

Impactful studies from ASCO 24 II: Combi-AD

Promising activity of brenetafusp in PD-L1 refractory…

No differences in PFS between the two study arms

Identifying patients with longterm benefits during…

Risultati promettenti: Tripla terapia di combinazione…

Prometedora actividad de brenetafusp en melanoma…

No hubo diferencias en la PFS entre los dos brazos del…

Encouraging developmental IO-options

New MOA in r/m HNSCC

New perspectives in HPV+ r/m HNSCC

New idea: anti-digest for EC?

De-escalation in ovarian cancer?